FeesSafety
Pluang+
Home/Explore/US Market Price/Stocks/CRSP
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Crispr Therapeutics AG (CRSP) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

CRISPR Therapeutics (CRSP) trades at $49.39, down 1.2% with a bearish technical outlook. The company shows significant financial challenges with negative revenue in 2025, gross profit margin of -1,691.26%, and consistent quarterly losses. However, analyst sentiment remains positive with 57.9% buy ratings and a $63.17 consensus price target, representing 28% upside potential. Recent news highlights upcoming clinical data presentations and commercial progress with CASGEVY gene therapy.
The stock presents a high-risk, high-reward opportunity with strong Wall Street support despite current financial losses. Key catalysts include upcoming clinical data readouts and CASGEVY commercialization progress, but investors face substantial execution risk and cash burn. The disconnect between negative fundamentals and optimistic analyst sentiment creates a speculative investment case dependent on pipeline success.
Read full analysis

Key Stats

  • Market Cap
    $4.74B
  • Volume
    1,065,670
  • Sector
    Health
  • 52W High
    $65.72
  • 52W Low
    $44.34
  • Typical Hold Time
    78 Days
  • Enterprise Value
    $3.16B
  • Div Yield
    -
  • Trading Activity
    0% Sell | 100% Buy
$49.5
52W Low: $44.34
30 Mar 2026
52W High: $65.72
27 Oct 2025

Track Crispr Therapeutics AG (CRSP) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Crispr Therapeutics AG has traded between a low of $44.34 and a high of $65.72, highlighting its annual price range. Buy and sell Crispr Therapeutics AG shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Most Recent News

Content is generated by Aura AI

CareCloud appoints Mitchell Brie as Chief Compliance Officer to boost its healthcare compliance services.

CareCloud has named Mitchell Brie as Chief Compliance Officer to lead its growing healthcare compliance business. Brie, founder of Empower Healthcare & Compliance Partners (acquired by CareCloud), will oversee corporate compliance and continue as Pre...

Market News
27 minutes ago
Na
Bullish
news icon
CareCloud appoints Mitchell Brie as Chief Compliance Officer to boost its healthcare compliance services.

Defense contractors must review CUI access before licensing Microsoft 365 Copilot in GCC High cloud.

eSoftware Associates advises defense contractors to carefully map controlled unclassified information (CUI) access permissions before licensing Microsoft 365 Copilot in the GCC High cloud environment. Moving to GCC High does not automatically grant c...

Market News
1 hour ago
Esoftware Associates
Neutral
Defense contractors must review CUI access before licensing Microsoft 365 Copilot in GCC High cloud.

Eviden launches ASTRA-LAS, a tactical aid system enhancing naval decision-making with AI and real-time data.

Eviden, part of Atos Group, has introduced ASTRA-LAS, a new AI-powered tactical assistant designed to support naval operations by providing enhanced visualizations, automated analyses, and mission-specific recommendations. This system helps naval off...

Market News
3 hours ago
Eviden/Atos Group
Bullish
news icon
Eviden launches ASTRA-LAS, a tactical aid system enhancing naval decision-making with AI and real-time data.
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions

All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $4.74B
  • Volume
    1,065,670
  • Sector
    Health
  • 52W High
    $65.72
  • 52W Low
    $44.34
  • Typical Hold Time
    78 Days
  • Enterprise Value
    $3.16B
  • Div Yield
    -
  • Trading Activity
    0% Sell | 100% Buy
$49.5
52W Low: $44.34
30 Mar 2026
52W High: $65.72
27 Oct 2025

Track Crispr Therapeutics AG (CRSP) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Crispr Therapeutics AG has traded between a low of $44.34 and a high of $65.72, highlighting its annual price range. Buy and sell Crispr Therapeutics AG shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!